
WGS Stock Forecast & Price Target
WGS Analyst Ratings
Bulls say
GeneDx Holdings Corp is experiencing robust growth in its core exome and genome revenue, reporting a remarkable 65% year-over-year increase, which contributed to an 11% beat on topline results and also exceeded bottom-line expectations. The company's strategic shift towards exome and genome testing has led to a significant improvement in average selling prices (ASPs), which rose by 23% year-over-year to $3,850 per test, bolstered by a favorable mix-shift towards higher-margin tests. Additionally, GeneDx has adjusted its 2025 revenue guidance upward to a range of $425-428 million, reflecting a solid growth trajectory of 39-40% year-over-year, underpinned by a 33% increase in core testing volume year-over-year.
Bears say
GeneDx Holdings Corp is facing a negative outlook primarily due to its anticipated cash burn of approximately $2 million per quarter and high denial rates for its tests, which stand at 45% in Q3 2024 despite contracts with around 80% of health plans. The company's reliance on third-party payers for adequate reimbursement poses a significant risk, as any alterations in reimbursement schedules or failure to meet compliance requirements could severely impact its commercial viability. Additionally, operational challenges related to maintaining a consistent supply of sequencers and materials, as well as disruptions in data and workflow services, further threaten GeneDx's financial health and overall results of operations.
This aggregate rating is based on analysts' research of GeneDx Holdings Corp and is not a guaranteed prediction by Public.com or investment advice.
WGS Analyst Forecast & Price Prediction
Start investing in WGS
Order type
Buy in
Order amount
Est. shares
0 shares